Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Free Cash Flow (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Free Cash Flow for 16 consecutive years, with $44.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 36.63% year-over-year to $44.9 million, compared with a TTM value of $208.6 million through Dec 2025, down 12.81%, and an annual FY2025 reading of $208.6 million, down 12.81% over the prior year.
  • Free Cash Flow was $44.9 million for Q4 2025 at Catalyst Pharmaceuticals, up from $32.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $72.6 million in Q3 2024 and bottomed at $2.9 million in Q1 2021.
  • Average Free Cash Flow over 5 years is $38.3 million, with a median of $36.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 59.75% in 2021, then surged 192.04% in 2022.
  • Year by year, Free Cash Flow stood at $19.1 million in 2021, then surged by 109.44% to $40.1 million in 2022, then soared by 38.62% to $55.6 million in 2023, then rose by 27.42% to $70.8 million in 2024, then plummeted by 36.63% to $44.9 million in 2025.
  • Business Quant data shows Free Cash Flow for CPRX at $44.9 million in Q4 2025, $32.4 million in Q3 2025, and $71.3 million in Q2 2025.